RxDoctor Payments DataLook up a doctor →

Mehrdad Ariani

Interventional Cardiology · Northridge, CANPI 1942496211

Payments from drug & device makers

$4,994,251in general payments, 2019–2025

Across 1,975 payments — averaging $2528.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1M
  • Astrazeneca UK Limited$997K
  • Eli Lilly$735K
  • CSL Behring$591K
  • Novo Nordisk AS$388K
  • Merck$300K
  • plus $940K from 54 others
$70,634in research payments, 2019–2025

Across 10 payments — averaging $7063.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$46K
  • Novo Nordisk AS$25K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis130$1,042,940
Astrazeneca UK Limited12$997,312
Eli Lilly20$735,173
CSL Behring152$591,348
Novo Nordisk AS256$387,547
Merck84$300,100
Amgen95$253,265
Sanofi US Services Inc.60$204,389
Boehringer Ingelheim International GmbH115$145,669
Impulse Dynamics (USA) Inc.52$85,669
Boehringer Ingelheim Pharma GmbH & Co.kg11$73,011
AstraZeneca105$68,353
Ionis Pharmaceuticals, Inc.11$40,738
Lexicon Pharmaceuticals, Inc.6$15,620
Novo Nordisk57$9,761
Boehringer Ingelheim41$8,793
Medicure Pharma Inc.3$7,133
Abbott105$5,770
Boston Scientific69$4,657
Organon1$2,500
Medtronic(2 entities)64$2,118
Johnson & Johnson104$2,090
Abiomed35$1,978
Pfizer73$1,081
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)74$855
Amarin Pharma, Inc.28$646
E.r. Squibb & Sons, L.L.C.33$538
Takeda Pharmaceuticals U.S.A., Inc.21$382
Sanofi-aventis U.S. LLC17$381
Bayer16$362
Actelion Pharmaceuticals US, Inc.16$347
Astellas Pharma US Inc6$322
Philips North America LLC3$313
Cvrx, Inc.5$308
Lilly USA, LLC13$301
Angiodynamics, Inc.4$266
Alnylam Pharmaceuticals Inc.11$236
Edwards Lifesciences4$192
Cathworks, Inc.3$191
Gilead12$168
GE HealthCare2$154
Penumbra, Inc.1$150
Heartflow, Inc.7$145
Kiniksa Pharmaceuticals International, PLC4$120
Esperion Therapeutics, Inc.5$116
Cardiovascular Systems Inc.1$90
Asahi Intecc USA, Inc.1$86
Biotronik Inc.5$80
Scpharmaceuticals Inc.3$66
Cleerly, Inc.1$59
Tactile Systems Technology Inc3$46
Reflow Medical Inc2$43
Kiniksa Pharmaceuticals, Ltd.1$31
Stryker1$30
Teleflex LLC1$30
Regeneron Healthcare Solutions, Inc.1$28
Daiichi Sankyo Inc.1$22
Cook Medical LLC1$19
Arbor Pharmaceuticals, Inc.1$19
Acist Medical Systems, Inc.1$18

How this compares

$4,994,251 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$1,399,432
Medicare patients
1,187
Services billed
8,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Northridge

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →